Drug intelligence / Profile preview

GIM-0621

Development stage: Preclinical
Lead developer: Georgiamune
Modality: Small Molecules

Overview

GIM-0621 is a first-in-class small molecule drug being developed by Georgiamune Inc. for the treatment of neoplasms (cancer). Its specific target and mechanism of action are currently undisclosed, but it is part of Georgiamune's pipeline of immunomodulators aimed at reprogramming immune responses to fight cancer and autoimmune diseases.

Beyond the preview

Go deeper on GIM-0621.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GIM-0621.

Explore the full profile